Paranoid cognitions Mental and Behavioural Disorders
Conditions
Interventions
All participants will receive Cannabidiol (CBD) on one occasion, and placebo on the other. The order of administrations will be randomised and double-blinded. The drugs will be administered as oral ca
Sponsors
King's College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-50 years 2. English as first language 3. Patient at OASIS service
Exclusion criteria
Exclusion criteria: 1. Subjects who have been diagnosed with a major mental or physical illness (epilepsy, schizophrenia, bipolar disorder) 2. Subjects must not have had previous treatment with antipsychotic or mood stabilising drugs 3. Pregnancy 4. Drug/alcohol dependence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Autonomic arousal using pulse and respiratory rates and saliva swabs to measure cortisol 2. Paranoid thinking using the State-Social Paranoid Scale and the Cape-(state version) 3. Affective processing using the Beck Anxiety Inventory, the Bond and Lader Visual Analogue Scale and the Negative-Self-Statement-Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Cognitive functioning using the Letter-Number-Span to measure working memory, and the Hopkins-Verbal-Learning-Task-Revised | — |
Countries
United Kingdom
Outcome results
None listed